Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report report published on Tuesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX stock opened at $3.74 on Tuesday. The business has a 50-day simple moving average of $4.74 and a two-hundred day simple moving average of $5.73. The company has a market capitalization of $48.58 million, a P/E ratio of 3.17 and a beta of 0.46. Eagle Pharmaceuticals has a 52-week low of $3.50 and a 52-week high of $23.52.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several institutional investors have recently bought and sold shares of EGRX. Strs Ohio bought a new position in Eagle Pharmaceuticals during the 3rd quarter valued at $145,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Eagle Pharmaceuticals by 11.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 191,635 shares of the specialty pharmaceutical company’s stock valued at $3,022,000 after purchasing an additional 20,204 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Eagle Pharmaceuticals by 66.5% during the third quarter. Assenagon Asset Management S.A. now owns 217,668 shares of the specialty pharmaceutical company’s stock valued at $3,433,000 after purchasing an additional 86,917 shares in the last quarter. Smith Graham & Co. Investment Advisors LP boosted its holdings in Eagle Pharmaceuticals by 1.4% during the third quarter. Smith Graham & Co. Investment Advisors LP now owns 273,099 shares of the specialty pharmaceutical company’s stock worth $4,307,000 after purchasing an additional 3,648 shares during the last quarter. Finally, Headlands Technologies LLC grew its position in Eagle Pharmaceuticals by 263.4% in the 3rd quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 1,686 shares in the last quarter. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.